The aim of this study was to determine the overall and disaggregated survival based on the Gleason score, age and extent of a patient cohort diagnosed with advanced prostate cancer according to standard clinical practice.
We used an observational and retrospective design for the study. For each patient, we recorded clinical variables such as the extent (metastatic or locally advanced), Gleason score, age, date of diagnosis, date of last contact with the health system and the vital status during the last contact. We used univariate and multivariate statistical techniques of survival. The parametric survival methods enabled us to calculate the mean survival using extrapolation. We analysed 219 patients treated in the public health system between 2008 and 2011. The analysis showed statistically significant differences in survival depending on Gleason score, age and stage. The longest survival was in the subgroup younger than 75 years, with a local extent and a low-risk category on the Gleason scale (19.41 years), and the shortest survival (0.97 years) was in the 75 years or older group. The survival of the other subgroups ranged between these outliers.
The main contribution of this study is that it is the first to calculate the mean survival of advanced prostate cancer in Spain in terms of the variables of our study population. This information helps clinicians predict the life expectancy of each patient according to their prognostic factors.
Actas urologicas espanolas. 2016 May 09 [Epub ahead of print]
J Campá, G Mar-Barrutia, J Extramiana, A Arróspide, J Mar
Servicio de Urología, Hospital Universitario de Álava, Vitoria-Gasteiz, España. Electronic address: ., Unidad de Investigación AP-OSI, Hospital Alto Deba, Arrasate-Mondragón, Bilbao, España., Servicio de Urología, Hospital Universitario de Álava, Vitoria-Gasteiz, España., Unidad de Investigación AP-OSI, Hospital Alto Deba, Arrasate-Mondragón, Bilbao, España; Red de Investigación en Servicios de Salud y Enfermedades Crónicas (REDISSEC), Bilbao, España; Instituto Biodonostia, Donostia-San Sebastián, España., Unidad de Investigación AP-OSI, Hospital Alto Deba, Arrasate-Mondragón, Bilbao, España; Red de Investigación en Servicios de Salud y Enfermedades Crónicas (REDISSEC), Bilbao, España; Instituto Biodonostia, Donostia-San Sebastián, España; Unidad de Gestión Sanitaria, Hospital Alto Deba, Arrasate-Mondragón, España.